Thanks to the Web and smartphones, we're used to receiving the data we need in the snap of a finger.
In the real world, that means you can be driving through a remote stretch of highway and find out who won the 1960 Olympic gold medal in fencing before the next song starts playing on the radio.
But when it comes to medical tests, the scene is still best described as "hurry up and wait."
Even in our fast-paced, high-tech society, it can take several days to find out if you have the markers for cancer or a stroke. Or for that matter a deadly disease.
That leaves many patients waiting, worrying, and wondering for days or even weeks. In some cases, lives are even lost.
That's why I'm happy to report that a key U.S. research lab has developed a breakthrough medical testing device that can speed up the results of your lab tests.
It is so fast, you'll get results before you leave the doctor's office.
Sandia's "Lab on a Chip"
As its name implies, the SpinDx system uses a spinning disk inside a portable instrument – much like a CD player – to manipulate blood samples.
Researchers say it can measure a patient's white blood cell count, analyze key protein markers, and process up to 64 tests from a single sample.
And all in a few short minutes…
By the end of this decade, SpinDx or a device like it will have a profound impact on the way doctors find and treat a wide range of diseases, from cancer to Alzheimer's.
Not only that, but the new SpinDx could prove a boon to investors, too.
Turns out Sandia, the research lab that made the product, wants to find backers from the private sector who could help get SpinDx to market. In announcing the new milestone platform earlier this month, the Sandia team said it's looking for a firm to license the rights to it.
This kind of activity is right up Sandia's alley.
Known as an elite lab, Sandia makes it a steady practice to work with the private sector. It has a huge portfolio of cutting-edge tech that's ready-made for licensing and technology transfers.
It even posts a long list of these projects on its website. You can browse a wide range of topics from biotech to nanoscience to software by clicking here.
Fact is, Sandia researchers boast a 60-year history of pushing the boundaries of high tech and science. A unit of defense giant Lockheed Martin Corp. (NYSE:LMT) runs the lab under contract for the U.S. Department of Energy.
With SpinDx, the idea is to take the platform to the masses, team members say.
"We envision medical personnel using SpinDx routinely," said Greg Sommer, a Sandia team leader. "Instead of standard blood panels and costly lab tests, a SpinDx disk would be processed right in the office [while the staff is still] gathering routine data like temperature and blood pressure."
The team touts the following features of SpinDx:
- Small sample size: Patients merely have to provide a pinprick sample of blood.
- Ease of use: Spinning disks will contain antibodies specific to each protein marker that denotes disease.
- Plug-and-play tech: For patient testing, a doctor can simply choose among a "cardiac disk," "immune disk," and other options.
- Low cost: The disks cost pennies to make.
- Quick response time: Doctors can have the results on their desktops in just 15 minutes.
But that's not all…
The Sandia team believes the SpinDx could improve food safety and thwart bioterrorists attacks, too. In both cases, the U.S. wants to safeguard against one of the worst toxins known to man – botulism.
Now, a substance related to botulism is used safely to make Botox. Millions of people have had this substance injected into their faces to fights the effects of wrinkles. And when it comes to food poisoning, only about 145 cases in the U.S. are reported each year.
Yet make no mistake – this is deadly stuff. A small amount of botulism injected into the food supply would send shockwaves through the nation…
And the food-testing capabilities of SpinDx could be the fastest and most accurate method of detecting it.
"Food processing plants are looking for something that can be integrated into their assembly lines," said Sommer. "Our device will be suitable because it's fast, inexpensive, and simple to operate."
Sandia is one of the reasons why I say high tech can save America. This time, I mean it literally. A device like this could save millions of us from threat of a biological attack. That alone makes it a great investment.
Related Articles and News:
- Money Morning:
If Anyone Knows How to Make Money It's This Hot Tech IPO
- Money Morning:
Cutting-Edge "Maple Seed" Drones are About to Reshape High-Tech Surveillance
- Money Morning:
Experimental Brain Injury Treatments Could Be Worth Billions
- Money Morning:
Breakthrough Tech Lets Users Surf the Web With Just Their Eyes
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.